629 related articles for article (PubMed ID: 20608327)
1. [Analysis of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Petrová P; Minarík J; Pika T; Bacovský J; Adamová D; Langová K;
Klin Onkol; 2010; 23(3):171-81. PubMed ID: 20608327
[TBL] [Abstract][Full Text] [Related]
2. [The comparison of serum levels of selected biomarkers in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Pika T; Bacovský J; Minarík J; Heinzová V; Langová K
Cas Lek Cesk; 2009; 148(7):315-22. PubMed ID: 19642297
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Pika T; Minarík J; Zemanová M; Bacovský J; Heincová V;
Vnitr Lek; 2006 Mar; 52(3):232-40. PubMed ID: 16722154
[TBL] [Abstract][Full Text] [Related]
4. [Contribution to the evaluation of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and in individual clinical stages of multiple myeloma].
Scudla V; Petrová P; Minarík J; Pika T; Budíková M; Bacovský J; Repovský S
Vnitr Lek; 2010 Jun; 56(6):591-601. PubMed ID: 20681472
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and different stages of multiple myeloma.
Scudla V; Petrova P; Minarik J; Pika T; Bacovsky J
Neoplasma; 2011; 58(6):499-506. PubMed ID: 21895403
[TBL] [Abstract][Full Text] [Related]
6. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A
Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
[TBL] [Abstract][Full Text] [Related]
7. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
[TBL] [Abstract][Full Text] [Related]
8. [Contribution to the evaluation of the relationship between angiogenic cytokines, selected biological parameters and prognostic factors in multiple myeloma].
Scudla V; Pika T; Budíková M; Ordeltová M; Minarík J; Zemanová M; Bacovský J; Srovnalík K;
Cas Lek Cesk; 2006; 145(12):929-35. PubMed ID: 17323615
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma].
Ščudla V; Petrová P; Pika T; Lochman P; Minařík J; Bačovský J; Srovnalík K
Cas Lek Cesk; 2015; 154(4):181-8. PubMed ID: 26357861
[TBL] [Abstract][Full Text] [Related]
10. The significance of soluble CD138 in diagnosis of monoclonal gammopathies.
Maisnar V; Tousková M; Tichý M; Krejsek J; Chrobák L; Voglová J; Malý J
Neoplasma; 2006; 53(1):26-9. PubMed ID: 16416009
[TBL] [Abstract][Full Text] [Related]
11. High serum interleukin-2 levels in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma.
Cimino G; Avvisati G; Amadori S; Di Gregorio AO; Magliocca V; Petrucci MT; Sgadari C
Nouv Rev Fr Hematol (1978); 1989; 31(5):329-32. PubMed ID: 2587201
[TBL] [Abstract][Full Text] [Related]
12. The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma.
Scudla V; Pika T; Budikova M; Petrova J; Minarik J; Bacovsky J; Langova K; Zivna J;
Neoplasma; 2010; 57(2):102-10. PubMed ID: 20099972
[TBL] [Abstract][Full Text] [Related]
13. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
Bergón E; Miravalles E; Bergón E; Miranda I; Bergón M
Clin Chem Lab Med; 2005; 43(1):32-7. PubMed ID: 15653439
[TBL] [Abstract][Full Text] [Related]
14. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the analytical performance and the sensitivity of serum free light chains immunoassay in patients with monoclonal gammopathy.
Wolff F; Thiry C; Willems D
Clin Biochem; 2007 Mar; 40(5-6):351-4. PubMed ID: 17239359
[TBL] [Abstract][Full Text] [Related]
16. The evolving use of serum free light chain assays in haematology.
Pratt G
Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
[TBL] [Abstract][Full Text] [Related]
17. [Monitoring markers of bone turnover in multiple myeloma].
Spicka I; Spacek P; Hulejová H; Procházka B; Cieslar P; Chrz M; Válková V; Klener P
Vnitr Lek; 1999 Aug; 45(8):463-7. PubMed ID: 11045145
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma].
Shimizu K; Itoh J; Sugiura I; Tsushita K; Kosugi H; Nagura E
Rinsho Ketsueki; 2006 Apr; 47(4):303-9. PubMed ID: 16715965
[TBL] [Abstract][Full Text] [Related]
19. [Soluble syndecan-1 levels in different plasma cell dyscrasias].
Jánosi J; Sebestyén A; Mikala G; Petö M; Jákó J; Domján G; Németh J; Kis Z; Kopper L; Vályi-Nagy I
Orv Hetil; 2005 Jan; 146(4):165-8. PubMed ID: 15751511
[TBL] [Abstract][Full Text] [Related]
20. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance.
Rajkumar SV; Kyle RA; Therneau TM; Clark RJ; Bradwell AR; Melton LJ; Larson DR; Plevak MF; Katzmann JA
Br J Haematol; 2004 Nov; 127(3):308-10. PubMed ID: 15491291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
